Business Wire

IPROOV

20.5.2020 09:02:10 CEST | Business Wire | Press release

Share
iProov Now Providing Facial Authentication for NHS Login Across Android and iOS

iProov , the world leader in spoof-resistant, biometric authentication technology, today announced that its technology has been deployed to verify users signing up to NHS login across Android and iOS. Following an initial launch on Android, iProov’s technology is now available on the iOS version of the NHS App.

This enables users in England to create their NHS login remotely, securely and conveniently at a time when they need it most, removing the need for manual and in-person verifications. The NHS App allows for easy and fast access to essential services such as GP appointments, access to medical records and ordering repeat prescriptions.

iProov’s Flashmark facial verification technology is now used by users to create an NHS login through the NHS App. Once a user submits a photo of their identity document, such as a valid passport or driving licence, they will be prompted to position their face correctly on the screen. Following a short sequence of flashing colours, the user’s identification will be verified and they will be able to access all the information and services the NHS App has to offer, following completion of all other checks including matching a user to their medical record.

The iProov process verifies that an individual is a real person, the right person, and is authenticating themselves right now. This protects against the risk of identity theft while giving people quicker and more convenient access to vital services wherever they are. It also frees up valuable NHS resources and saves money, as NHS Digital now needs to process far fewer manual applications. More than a million people have now registered with NHS login, with a peak of over 60,000 new IDs verified during the first week of April. The combined iProov and NHS solution has proven its ability to cope with an unprecedented increase in demand.

Andrew Bud, Founder and CEO, iProov said: “The NHS login service is now a proven, secure, inclusive and effective way for citizens to verify and use their identity for health-related purposes. We have been very impressed by what the NHS Digital team has accomplished, by their agility and professionalism, and by the boldness of their vision.

“This is particularly important in the current climate in which demand is unprecedented and the need for convenient and robust remote identity verification is crucial. We are delighted to be playing our part.”

Melissa Ruscoe, Programme Head for NHS login, said: “iOS users are now able to benefit from faster automatic identity verification when creating their NHS login, giving them a single safe and secure way to access their digital healthcare services such as the NHS App.

“Over the past couple of months we have seen a surge in demand in people registering for an NHS login as they look to manage their health digitally.

“More automated tools like this will help us to improve the experience of our users, increase demand capacity and ensure nobody is waiting too long to complete identity verification checks to gain access to their digital healthcare services.”

In addition to NHS login, iProov’s unique patented technology is used to verify identities in the Home Office ‘EU Exit: ID Document Check’ app which enables European citizens to apply to the EU Settlement Scheme. iProov also provides governments, banks and other enterprises with Genuine Presence Assurance, including the US Department for Homeland Security, allowing them to authenticate users remotely on smartphones or other devices.

ENDS

About iProov
Founded in 2011, iProov is a world leader in spoof-resistant, biometric facial authentication technology. Its technology is used by banks and governments around the world for secure customer onboarding, logon and authentication, to ensure new and returning users are genuine, and to guard against fraudulent attempts to gain access to personal data. For more information, see www.iproov.com .

About NHS login
NHS login is a service that has been created by the NHS for patients and the public. It provides a re-usable way for patients to access multiple digital health and social care services with a single login, which includes authentication for returning users.

NHS login can be used by the public to securely access their health and care information wherever they see the NHS login button. People can use NHS login to prove who they are safely and securely and, in most cases, without the need to visit their GP.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Landmark Global Galderma Survey Shows 9 out of 10 People Are Affected by Skin Quality Concerns7.7.2026 07:00:00 CEST | Press release

World’s most extensive skin quality profiling survey of more than 11,000 people across Europe, Asia, and the Americas finds that nine out of ten people are affected by skin quality concerns, with the most important attributes of good skin quality identified as smooth, hydrated and glowing skin1 Results show that skin quality has an impact on quality of life for 85% of people, with more than a third feeling self-conscious, insecure or anxious due to poor skin quality1 In response to clinicians’ calls for a universal assessment tool to help address these concerns, Galderma supported leading experts in the development of the Skin Quality Assessment Scale; a holistic, science-based tool to evaluate skin quality comprehensively and guide personalized, long-term treatment planning2 At Galderma, we champion skin quality by providing insights, tools, and solutions to better understand and address a wide spectrum of concerns, helping people take pride and feel comfortable in their own skin at e

Morinaga Milk Achieves Self-Affirmed GRAS Status for LAC-Living+™, Expanding U.S. Opportunities for Its Postbiotic Ingredient7.7.2026 04:00:00 CEST | Press release

Clinical evidence–backed postbiotic supports mood and well-being with formulation flexibility for diverse applications Morinaga Milk Industry Co., Ltd. (TOKYO:2264), a leading Japanese dairy and functional ingredient company, today announced that it has achieved self-affirmed GRAS (Generally Recognized As Safe) status in the United States for LAC-Living+™ (L. helveticus MCC1848), its proprietary postbiotic ingredient. This milestone expands the commercial availability of LAC-Living+ in the U.S. market and enables its use in dietary supplements, functional foods, and beverages, supporting the development of products designed to address growing consumer demand for health and well-being solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706806943/en/ Growing Interest in Postbiotics and Mental Well-Being Consumer interest in proactive health management has expanded significantly in recent years, alongside increasing aw

Access Advance Welcomes New Licensors to the Video Distribution Patent Pool7.7.2026 02:00:00 CEST | Press release

Access Advance LLC today announced that Sharp, M&K Holdings, Tagivan and 9 other patent owners who own substantial video codec patent portfolios that cover the core technologies behind video decoding, processing, and streaming media delivery, have joined the Video Distribution Patent Pool (VDP Pool) in the first half of 2026. "The addition of all of these new Licensors’ patent portfolios is a real win for both the VDP Pool and our many existing and future Licensees,” said Peter Moller, CEO of Access Advance. “These companies have broad and deep patent portfolios and further enhance the program’s market leading position in resolving the licensing issues around the use of modern video codecs across all the diverse business models of internet video streaming.” The following patent holders have joined the VDP Pool as Licensors in the first half of 2026: Digital Insights Inc. Hanbat National University Industry-Academic Cooperation Foundation Hanwha Vision Co., Ltd. Industry-Academy Coopera

Real Chemistry Announces New Asia Pacific Hub with Acquisition of Spurwing Communications in Singapore7.7.2026 01:00:00 CEST | Press release

Expanded footprint advances the company’s global strategy in key growth region for healthcare and pharma brands Real Chemistry, a global leader in AI- and insights-driven healthcare communications, today announced the acquisition of Spurwing Communications, establishing the company’s first Asia Pacific (APAC) strategic hub in Singapore. This milestone strengthens Real Chemistry’s global strategy and presence in APAC, enhancing its ability to support healthcare organizations. Combining deep market expertise with globally integrated capabilities across analytics, medical communications, advertising and strategic communications, the company is well positioned to deliver more connected, local insight-driven support — ultimately helping clients better reach and engage healthcare professionals, patients and caregivers across the region. “APAC is fast becoming one of the most dynamic and strategically important regions for healthcare innovation and access to life-improving therapies,” said Ka

Vertex to Acquire Crinetics Pharmaceuticals6.7.2026 22:04:00 CEST | Press release

- Crinetics adds potential best-in-class commercialized and Phase 3 endocrinology assets with ~$5 billion peak sales opportunity to Vertex’s portfolio - - PALSONIFY®, Crinetics’ recently launched, first and only, once-daily oral therapy for adults with acromegaly has demonstrated strong and growing early uptake - - Atumelnant, a once-daily oral adrenocorticotropic hormone (ACTH) receptor antagonist in Phase 3 development for congenital adrenal hyperplasia (CAH), has shown unique and transformative potential to both normalize androgen levels and enable management of patients with physiologic levels of glucocorticoids, the true goal of CAH management; atumelnant has also demonstrated therapeutic potential in patients with Cushing’s syndrome - - Acquisition adds to Vertex’s innovation pipeline, accelerates Vertex’s revenue growth and enhances long-term earnings profile - - Vertex to host investor call today, July 6 at 4:30 p.m. ET - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and C

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye